300896.SHE Imeik Technology Development Co
- Market cap
- CNY 26.9B
- P/E
- 27.1x
- P/B
- 3.37x
- ROE
- 13.4%
- Dividend yield
- 5.61%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300896.SHE undervalued?
Graham number300896.SHE trades 101.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Imeik Technology Development Co fundamental analysis
No fundamental analysis for Imeik Technology Development Co yet.
Imeik Technology Development Co stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Imeik Technology Development Co
Imeik Technology Development Co.,Ltd. engages in the research and development, and transformation of biomedical materials and biopharmaceutical products in China. The company offers aesthetic medicine products, such as cross-linked sodium hyaluronate gel with PLLA-b-PEG microsphere; poly facial implant thread; medical sodium hyaluronate-hydroxypropyl methylcellulose gel; sodium hyaluronate composite solution for injection; modified sodium hyaluronate gel for injection; medic…
Full company profileImeik Technology Development Co financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Imeik Technology Development Co annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 141M | 222M | 321M | 558M | 709M | 1.45B | 1.94B | 2.87B | 3.03B | 2.42B | 2.33B |
| Gross Profit | 122M | 192M | 286M | 517M | 651M | 1.36B | 1.84B | 2.73B | 2.86B | 2.19B | 2.14B |
| Operating Income | 62.0M | 93.7M | 143M | 350M | 503M | 1.13B | 1.49B | 2.16B | 2.29B | 1.32B | 1.17B |
| EBITDA | 64.9M | 96.2M | 151M | 361M | 514M | 1.13B | 1.51B | 2.19B | 2.31B | 1.39B | 1.26B |
| Net Income | 53.4M | 82.2M | 123M | 306M | 440M | 958M | 1.26B | 1.86B | 1.96B | 1.29B | 1.05B |
| EPS | 0.25 | 0.36 | 0.54 | 1.35 | 1.79 | 3.16 | 4.17 | 6.15 | 6.50 | 4.28 | 3.49 |
| Balance Sheet | |||||||||||
| Total Assets | 314M | 396M | 464M | 744M | 4.67B | 5.27B | 6.26B | 6.85B | 8.34B | 8.91B | 9.02B |
| Total Liabilities | 48.4M | 68.1M | 58.9M | 80.9M | 140M | 242M | 313M | 367M | 390M | 743M | 519M |
| Shareholders' Equity | 263M | 325M | 398M | 659M | 4.53B | 5.03B | 5.85B | 6.35B | 7.80B | 7.58B | 7.84B |
| Cash & Short-term Investments | 178M | 214M | 266M | 506M | 4.30B | 3.63B | 3.84B | 3.64B | 4.39B | 3.38B | 920M |
| Total Debt | 2.07M | 5.51M | 1.97M | - | 39.0M | 40.2M | 48.4M | 37.5M | 26.0M | 10.0M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 55.0M | 84.2M | 135M | 310M | 426M | 943M | 1.19B | 1.95B | 1.93B | 1.39B | - |
| Capital Expenditure | 54.3M | 42.6M | 39.2M | 32.6M | 32.1M | 23.0M | 156M | 63.7M | 239M | 171M | 146M |
| Free Cash Flow | 662K | 41.6M | 96.3M | 277M | 394M | 920M | 1.04B | 1.89B | 1.69B | 1.22B | 851M |
| Ratios | |||||||||||
| ROE | 20.3% | 25.3% | 30.8% | 46.4% | 9.7% | 19.0% | 21.6% | 29.3% | 25.1% | 17.0% | 13.4% |
| ROA | 17.0% | 20.7% | 26.5% | 41.1% | 9.4% | 18.2% | 20.2% | 27.1% | 23.5% | 14.5% | 11.7% |
| Net Profit Margin | 37.9% | 36.9% | 38.3% | 54.8% | 62.0% | 66.2% | 65.2% | 64.8% | 64.7% | 53.3% | 45.4% |
| Debt to Equity | 0.01x | 0.02x | 0.00x | - | 0.01x | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Imeik Technology Development Co dividends
- Dividend yield
- 5.61%
- Forward dividend
- 1.80 CNY
- Payout ratio
- 116.7%
- Ex-dividend date
- Sep 3, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.51B | 5.00 | 116.7% |
| 2024 | CNY 500M | 1.66 | 25.5% |
| 2023 | CNY 1.00B | 3.32 | 54.1% |
| 2022 | CNY 454M | 1.50 | 36.0% |
| 2021 | CNY 421M | 1.39 | 43.9% |
| 2020 | CNY 421M | 1.71 | 95.7% |
| 2019 | CNY 45.0M | 0.20 | 14.7% |
| 2018 | CNY 49.7M | 0.22 | 40.4% |
| 2017 | CNY 20.2M | 0.09 | 24.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Apr 29, 2024.
Who owns Imeik Technology Development Co
- Insiders 59.45%
- Institutions 5.63%
- Public & others 34.92%
- Shares outstanding 303M
- Free float 129M
Imeik Technology Development Co company profile
- Company name
- Imeik Technology Development Co
- Ticker
- 300896.SHE
- ISIN
- CNE100004868
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,458
- Fiscal year end
- December
- Address
- Shimao Building, Beijing, China, 100022
- Phone
- 86 10 8580 9026
- Website
- imeik.net/cn
About Imeik Technology Development Co
Imeik Technology Development Co.,Ltd. engages in the research and development, and transformation of biomedical materials and biopharmaceutical products in China. The company offers aesthetic medicine products, such as cross-linked sodium hyaluronate gel with PLLA-b-PEG microsphere; poly facial implant thread; medical sodium hyaluronate-hydroxypropyl methylcellulose gel; sodium hyaluronate composite solution for injection; modified sodium hyaluronate gel for injection; medical PVA gel ball-sodium hyaluronate-hydroxypropyl methylcellulose gel; and skin care products. It serves medical aesthetic institutions. The company was incorporated in 2004 and is headquartered in Beijing, China.
Imeik Technology Development Co management
4- Mr. Yifeng ShiGM & Director · born 1974
- Mr. Renchao ZhangChief Financial Officer · born 1979
- Liu DanAccounting Supervisor
- Ms. Dong Mei LiDeputy GM & Board Secretary · born 1984